Bupivacaine
DURECT Announces Submission of New Drug Application for POSIDUR™ (SABER®-Bupivacaine)
“We’re extremely pleased to submit this NDA for POSIDUR to the FDA. If approved by the FDA, POSIDUR will provide a non-opioid alternative treatment option for post-surgical pain,” James E. Brown, D.V.M., President and CEO of DURECT, stated, “Treating post-surgical pain with a true long-acting local anesthetic has the potential benefit of reducing the need for opioids and their associated systemic side effects that can prolong the time to recovery…
View original post 188 more words
Leave a comment